Literature DB >> 6230850

Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic islets.

B Hellman, J Sehlin, I B Täljedal.   

Abstract

Six hypoglycaemic sulphonylurea compounds were compared with regard to their ability to bind to beta-cell-rich pancreatic islets microdissected from ob/ob-mice. Glibenclamide differed from carbutamide, tolbutamide, chlorpropamide, glibornuride and glipizide in not being rapidly bound to an equilibrium, but accumulating progressively in amounts far exceeding the water space. An inhibitor of the anion channels in the beta-cell membrane, 4-acetamido-4'-isothiocyanate-stilbene-2,2'-disulphonic acid (SITS), suppressed the islet uptake of glibenclamide and to some extent also that of carbutamide and glibornuride. The unusual uptake characteristics of glibenclamide had their counterpart in a retardation of its maximal action in promoting the entry of Ca2+ into the beta-cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230850     DOI: 10.1530/acta.0.1050385

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  19 in total

1.  Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.

Authors:  A Holstein; A Plaschke; C Hammer; E-H Egberts
Journal:  Eur J Clin Pharmacol       Date:  2003-04-16       Impact factor: 2.953

2.  Distinct mechanisms for two amplification systems of insulin release.

Authors:  J C Henquin; M Bozem; W Schmeer; M Nenquin
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

3.  Internalization of 3H-glibenclamide in pancreatic islet cells.

Authors:  J L Carpentier; F Sawano; M Ravazzola; W J Malaisse
Journal:  Diabetologia       Date:  1986-04       Impact factor: 10.122

4.  Contributions of human cytochrome P450 enzymes to glyburide metabolism.

Authors:  Lin Zhou; Suresh B Naraharisetti; Li Liu; Honggang Wang; Yvonne S Lin; Nina Isoherranen; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Biopharm Drug Dispos       Date:  2010-05       Impact factor: 1.627

5.  Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide.

Authors:  M G Garrino; W Schmeer; M Nenquin; H P Meissner; J C Henquin
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

Review 6.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

7.  Sulphonylureas and hypoglycaemia.

Authors:  R E Ferner; H A Neil
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

Review 8.  Interaction of sulfonylurea with the pancreatic B-cell.

Authors:  E Gylfe; B Hellman; J Sehlin; B Täljedal
Journal:  Experientia       Date:  1984-10-15

9.  The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

Authors:  Kevin M Pantalone; Michael W Kattan; Changhong Yu; Brian J Wells; Susana Arrigain; Anil Jain; Ashish Atreja; Robert S Zimmerman
Journal:  Diabetes Care       Date:  2010-03-09       Impact factor: 19.112

10.  Morphological localisation of sulfonylurea receptor 1 in endocrine cells of human, mouse and rat pancreas.

Authors:  Y Guiot; M Stevens; I Marhfour; P Stiernet; M Mikhailov; S J H Ashcroft; J Rahier; J-C Henquin; C Sempoux
Journal:  Diabetologia       Date:  2007-06-26       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.